World’s first personalized mRNA cancer vaccine succeeds in US Phase 3 trial
SMRTR summary
Moderna and Merck's personalized mRNA cancer vaccine, intismeran, successfully met its Phase 3 trial goals when combined with Keytruda, cutting melanoma's return risk by 49% over five years. Custom-built for each patient's tumor, this breakthrough could reshape cancer treatment, with trials expanding to lung, bladder, and kidney cancers.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article